Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report)’s stock price fell 9.1% during trading on Tuesday . The stock traded as low as $22.03 and last traded at $22.34. 517,592 shares traded hands during mid-day trading, an increase of 933% from the average session volume of 50,104 shares. The stock had previously closed at $24.57.
Neoleukin Therapeutics Stock Performance
The company’s 50-day moving average price is $42.80 and its 200 day moving average price is $39.28. The stock has a market capitalization of $209.95 million, a PE ratio of -7.18 and a beta of 1.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Read More
- Five stocks we like better than Neoleukin Therapeutics
- Best Stocks Under $5.00
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- How to Invest in Blue Chip Stocks
- Netflix Is On Track To Hit $1,000 By Christmas
- How to Find Undervalued Stocks
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
